Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Fermented Wheat Germ Protein with Histone Deacetylase Inhibitor AR42 Demonstrates Enhanced Cytotoxicity against Lymphoma Cells In Vitro and In Vivo.
Journal: International journal of molecular sciences
Published: May 22, 2024
A Fermented Wheat Germ Extract Contains Protein Components Active against NSCLC Xenografts In Vivo.
Journal: Current issues in molecular biology
Published: August 02, 2023
Novel mTORC1 Inhibitors Kill Glioblastoma Stem Cells.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: October 06, 2020
A phase II study of bortezomib in combination with pegylated liposomal doxorubicin for acute myeloid leukemia.
Journal: American journal of hematology
Published: May 01, 2019
A phase I trial of escalating doses of cixutumumab (IMC-A12) and sorafenib in the treatment of advanced hepatocellular carcinoma.
Journal: Cancer chemotherapy and pharmacology
Published: February 02, 2018
The HB22.7-vcMMAE antibody-drug conjugate has efficacy against non-Hodgkin lymphoma mouse xenografts with minimal systemic toxicity.
Journal: Cancer immunology, immunotherapy : CII
Published: July 09, 2015
Efficacy of Combined Histone Deacetylase and Checkpoint Kinase Inhibition in a Preclinical Model of Human Burkitt Lymphoma.
Journal: Molecular medicine (Cambridge, Mass.)
Published: February 11, 2015
Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma.
Journal: British journal of haematology
Published: August 12, 2013
Targeting CD22 in B-cell malignancies: current status and clinical outlook.
Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Published: May 23, 2013
Last Updated: 09/26/2026